Encompass Health Q2 Earnings Beat Estimates, Stock Up 7.4%

Encompass Health Corp (EHC) reported robust Q2 2025 results, with adjusted EPS of $1.40, surpassing estimates by 16.7% and growing 26.1% year-over-year, and net operating revenues rising 12% to $1.5 billion. This strong performance was driven by increased net patient revenue per discharge and strategic capacity expansion, including new de novo hospitals and bed additions, despite elevated operating expenses. Consequently, EHC raised its full-year 2025 guidance for net operating revenues, adjusted EBITDA, and adjusted EPS, signaling management's confidence in continued growth and contributing to a 7.4% share price increase since the announcement.

Analysis

Encompass Health Corp. (EHC) reported a robust second quarter for 2025, significantly outperforming market expectations and leading to a 7.4% share price increase. The company posted an adjusted EPS of $1.40, a 16.7% beat on consensus estimates and a 26.1% year-over-year increase, driven by a 12% rise in net operating revenues to $1.5 billion. This top-line strength was underpinned by solid operational execution, including a 7.2% growth in total discharges and a 4.2% increase in net patient revenue per discharge, both surpassing estimates. The performance was further supported by strategic capacity expansion, with 26 new beds added and a de novo hospital opened. While operating expenses rose 10.4% due to higher labor costs, this was more than offset by revenue growth, resulting in a 17.4% year-over-year increase in adjusted EBITDA. Management's confidence is reflected in an upgraded full-year 2025 outlook, with the midpoint of the revised adjusted EPS guidance suggesting an 18.1% growth from the 2024 figure. The company's strong financial position is also evident from a 30.5% increase in adjusted free cash flow, a reduction in long-term debt, and enhanced capital returns through an increased dividend and ongoing share buybacks.

Key Decisions for Investors

• Given the strong earnings beat and significantly raised full-year guidance for revenue, EBITDA, and EPS, investors should consider the fundamental strength supporting the recent stock appreciation.
• It is prudent to monitor operating expense trends, particularly salaries and benefits, as the 10.4% year-over-year cost increase represents a key headwind that could pressure margins if not managed alongside revenue growth.
• Evaluate the company's balanced and shareholder-friendly capital allocation, where aggressive growth investments like de novo hospitals are paired with increased dividends, share repurchases, and debt reduction, signaling financial discipline.
• For longer-term positioning, track the execution of the reaffirmed 2023-2027 growth targets, as achieving the projected 6-8% CAGR in discharges is fundamental to the long-term investment thesis.